HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced it has received final clearance and approval from the Florida Agency for Health Care Administration to proceed closing of the Dura Medical acquisition, in connection with its change of ownership applications, a key regulatory step for closing. Dura is revenue generating and EBITDA positive. The acquisition is expected to be accretive to revenue and EBITDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride from Ketamine Products
- NRx files Citizen Petition with FDA seeking removal of BZT from ketamine
- NRX Pharmaceuticals’ Innovative Approaches in Mental Health Treatment Drive Buy Rating
- NRx Pharmaceuticals (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference
- NRx Pharmaceuticals (NASDAQ: NRXP) Charts Dual-Path for NRX-100